Phase 4
Completed N=4
Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population
Anesthesia, Local
Source: ClinicalTrials.gov NCT04298099 ↗
Enrolled (actual)
4
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Ropivacaine Concentrations — 0; 0; 1232.25; 850.25 ng/mL
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The primary aim of this study is to evaluate the pharmacokinetics of serum ropivacaine concentrations following erector spinae plane peripheral nerve blocks in the pediatric population.
Secondary outcomes will assess the efficacy of the block with perioperative morphine equivalent consumption and pain scores.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ropivacaine Concentrations |
0; 0; 1232.25; 850.25; 776.25; 518 | — |
| SECONDARY Post-anesthesia Care Unit Pain Scores Using FLACC Scale |
— | — |
| SECONDARY Post-anesthesia Care Unit Pain Scores Using FACES Pain Rating Scale |
— | — |
| SECONDARY Post-anesthesia Care Unit Pain Scores Using VAS |
5; 1.68; 6 | — |
| SECONDARY Morphine Equivalents |
5; 1.68; 0; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Age: 6 months - 95% percentile
Data sourced from ClinicalTrials.gov (NCT04298099). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.